榄香烯乳注射液联合替莫唑胺治疗对脑胶质瘤患者术后生存期及血清miR-720、miR-375水平的影响

doi:10.3969/j.issn.1671-7171.2023.03.006

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1152 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨榄香烯乳注射液联合替莫唑胺治疗对脑胶质瘤患者术后生存期及血清miR-720、miR-375水平的影响。【方法】回顾性分析2018年7月至2019年7月本院收治的78例行手术治疗的脑胶质瘤患者的临床资料,根据治疗方法的不同将其分为对照组(术后采用替莫唑胺治疗)和观察组(术后采用榄香烯乳注射液联合替莫唑胺化疗治疗),每组39例。比较两组治疗前后血清肿瘤标志物水平[表皮生长因子(EGF)、白细胞介素-2(IL-2)、血管内皮生长因子(VEGF)、白细胞介素-6(IL-6)]、免疫功能指标(T淋巴细胞CD3⁺、CD4⁺、CD4⁺/CD8⁺)及血清miR-375、miR-720水平,并比较两组近期疗效、远期生存率及中位生存期。【结果】观察组总有效率为84.62%(33/39),高于对照组的64.10%(25/39),差异有统计学意义(P<0.05)。治疗后,观察组血清EGF、VEGF、IL-2、IL-6水平低于对照组(P<0.05);观察组CD3⁺、CD4⁺、CD4⁺/CD8⁺高于治疗前,对照组CD3⁺、CD4⁺、CD4⁺/CD8⁺低于治疗前,且观察组高于对照组(P<0.05);观察组血清miR-375相对表达量高于对照组,miR-720相对表达量低于对照组(P<0.05)。随访2年发现,观察组1年生存率、2年生存率及中位生存期均高于对照组(P<0.05)。【结论】榄香烯乳注射液联合替莫唑胺治疗胶质瘤临床疗效较好,可改善患者免疫功能,调控血清miR-720、miR-375表达,可延长患者生存期。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	房敏
	刘燕
	崔建桥

关键词 ：脑肿瘤/外科学, 神经胶质瘤, 榄香烯/治疗应用, 替莫唑胺/治疗应用, 微RNAs, 无进展生存期

Abstract：【Objective】 To investigate the effects of elemene emulsion injection combined with temozolomide on postoperative survival and serum miR-720 and miR-375 levels in patients with glioma. 【Methods】 The clinical data of 78 patients with gliomas undergoing surgical treatment admitted to our hospital from July 2018 to July 2019 were retrospectively analyzed. According to the different treatment methods,they were divided into a control group (treated with temozolomide after surgery) and an observation group (treated with elemene emulsion injection combined with temozolomide after surgery),with 39 patients in each group. The levels of serum tumor markers [epidermal growth factor (EGF),interleukin-2 (IL-2),vascular endothelial growth factor (VEGF),interleukin-6(IL-6)],immune function indicators (T-lymphocyte CD3⁺,CD4⁺,CD4⁺/CD8⁺),and serum miR-375 and miR-720 before and after treatment were compared,and the short-term efficacy and long-term survival rate of the two groups were compared. 【Results】 The total effective rate in the observation group was 84.62% (33/39),higher than 64.10% (25/39) in the control group,with a statistically significant difference (P<0.05). After treatment,the levels of serum EGF,VEGF,IL-2 and IL-6 in the observation group were lower than those in the control group (P<0.05); The levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in the observation group were higher than those before treatment,while the levels of CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in the control group were lower than those before treatment,and the levels in the observation group were higher than those in the control group (P<0.05); The relative expression of miR-375 in the observation group was higher than that in the control group,while the relative expression of miR-720 in the observation group was lower than that in the control group (P<0.05). During a two-year follow-up,it was found that the 1-year survival rate,2-year survival rate,and median survival period in the observation group were higher than those in the control group (P<0.05). 【Conclusion】 Elemene emulsion injection combined with temozolomide has a good clinical efficacy in the treatment of glioma,which can improve the immune function of patients,regulate the expression of miR-720 and miR-375 in serum,and contribute to prolonging the survival period of patients.

Key words： Brain Neoplasms/SU Glioma Elemene/TU Temozolomide/TU MicroRNAs Progression-Free Survival

收稿日期: 2022-06-20

中图分类号:

R739.41

基金资助:开封市科技发展计划项目(编号:1603022)

引用本文:

房敏, 刘燕, 崔建桥. 榄香烯乳注射液联合替莫唑胺治疗对脑胶质瘤患者术后生存期及血清miR-720、miR-375水平的影响[J]. 医学临床研究, 2023, 40(3): 340-343.
FANG Min, LIU Yan, CUI Jian-qiao. Effects of Elemene Emulsion Injection Combined with Temozolomide on Postoperative Survival and Serum miR-720 and miR-375 Levels in Patients with Glioma. JOURNAL OF CLINICAL RESEARCH, 2023, 40(3): 340-343.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.03.006 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I3/340

[1] 朱传营,蒋马伟,周仁华,等.尼妥珠单抗联合放化疗治疗儿童脑干胶质瘤的临床研究[J].中国癌症杂志,2019,29(9):730-735.
[2] 顾润环,朱尔春.替莫唑胺联合放疗治疗恶性脑胶质瘤患者的临床研究[J].中国临床药理学杂志,2020,36(10):1202-1204.
[3] 李德培.脑胶质瘤临床诊疗新进展[J].国际神经病学神经外科学杂志,2020,47(1):87-90.
[4] 胥瑞婷,马音,朱炜炜.中药提取物榄香烯抗肿瘤临床应用现况[J].陕西中医,2021,42(9):1317-1320.
[5] 《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中华医学杂志,2016,96(7):485-509.
[6] 刘臣,李根华,李想.脑胶质瘤综合治疗的研究进展[J].中国微侵袭神经外科杂志,2019,24(4):182-185.
[7] 陈明生,赵海康,程莹莹,等.维生素C联合替莫唑胺对胶质瘤细胞的毒性作用及其机制[J].中国应用生理学杂志,2020,36(6):616-621.
[8] 李琳坤,张辰,刘飒,等.顺铂联合替莫唑胺治疗高级别脑胶质瘤术后患者的效果分析[J].实用癌症杂志,2019,34(1):100-102.
[9] 李秀英,张勇,冯旭东,等.调强放疗联合替莫唑胺对高级别脑胶质瘤术后患者免疫功能和生活质量的影响[J].现代生物医学进展,2021,21(16):3187-3191.
[10] 范瑞娟,王瑾,郭醒爽,等.榄香烯乳联合化疗对Lewis肺癌的影响及机制[J].实用癌症杂志,2021,36(11):1746-1749.
[11] 王威,汪文靖,吴学群,等.贝伐珠单抗联合调强放射治疗脑胶质瘤术后患者疗效及其对血清肿瘤标志物的影响[J].疑难病杂志,2019,18(2):132-135.
[12] 韩健美,李嘉阳,巴月,等.CRBGP通过抑制FAK-AKT通路和白介素-6的分泌抑制胶质瘤U251细胞的活性[J].生物化学与生物物理进展,2022,49(1):48-61.
[13] 盖晓惠,薛晓英.miRNA与胶质瘤关系及耐药机制的研究[J].脑与神经疾病杂志,2021,29(12):786-790.
[14] 熊志伟,刘少波,谢志敏,等.基于Wnt通路分析沉默miR-720对脑胶质瘤细胞生物学行为的影响[J].河北医药,2021,43(8):1152-1155.
[15] XU X,LIU Y,LI Y,et al.Selective exosome exclusion of miR-375 by glioma cells promotes glioma progression by activating the CTGF-EGFR pathway[J].J Exp Clin Cancer Res,2021,40(1):16.